Search by Medical Condition
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for Meningeal Carcinomatosis
- Immune Checkpoint Inhibitors Intrathecal Injection in Patients With Leptomeningeal Metastases in NSCLC
- Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC
- Treatment for Breast Cancer Patients With Meninges Invaded by Tumor Cells
- Intrathecal Double Checkpoint Inhibition
- Clinical Observation of ICI Combined With Recombinant Human Endostatin on Leptomeningeal Metastasis of Lung Cancer
- Intra-pemetrexed Alone or Combined With Concurrent Radiotherapy for Leptomeningeal Metastasis
- Intrathecal Pemetrexed for Leptomeningeal Metastasis
- A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis
- Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation
- Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases
- Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis
- Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung Cancer
- A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY)
- Pembrolizumab And Lenvatinib In Leptomeningeal Metastases
- Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer
- Efficacy and Safety of Durvalumab in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis
- Efficacy and Safety of Recombinant Human Endostatin in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis
- Study of Osimertinib in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation
- GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal Metastases
- Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis
- Avelumab With Radiotherapy in Patients With Leptomeningeal Disease
- BATs in Patients With Breast Cancer and Leptomeningeal Metastases
- ANG1005 in Leptomeningeal Disease From Breast Cancer
- Concurrent Intrathecal-pemetrexed and Involved-field Radiotherapy for Leptomeningeal Metastasis From Solid Tumors
- Study of AZD9291 in NSCLC Patients Harboring T790M Mutation Who Failed EGFR TKI and With Brain and/or LMS
- Intrathecal Pemetrexed for Recurrent Leptomeningeal Metastases From Non-small Cell Lung Cancer
- Pembrolizumab in Patients With Leptomeningeal Disease
- Concurrent Involved-field Radiotherapy and Intrathecal Chemotherapy for Leptomeningeal Metastases From Solid Tumors
- Study of Concurrent Intravenous and Intrathecal Nivolumab for Patients With Leptomeningeal Disease (LMD)
- Ipilimumab and Nivolumab in Leptomeningeal Metastases
- Expanded Access to ANG1005 for Individual Patients
- Phase II Study of Intraventricular Methotrexate in Children With Recurrent or Progressive Malignant Brain Tumors
- Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases
- Different Dose of Methotrexate for the Treatment of Meningeal Carcinomatosis
- Clinical and Pharmacological Study With 2B3-101 in Patients With Breast Cancer and Leptomeningeal Metastases
- Interest of Intrathecal Chemotherapy With Liposomal Cytarabine (DepoCyte®) in Meningeal Metastasis of Breast Cancer
- Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous System
- A Clinical Trial to Assess the Safety & Efficacy of the Treatment of Patients With Metastasis From Malignant Melanoma - Treatment Consists of the Substances Lomustine (Capsules) & Cytarabine (Injected Into an Area Near the Spinal Cord), Accompanied
- Continuous Intraventricular Methotrexate in Treating Patients With Leptomeningeal Disease
- Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis
- Bevacizumab With Etoposide and Cisplatin in Breast Cancer Patients With Brain and/or Leptomeningeal Metastasis
- Liposomal Cytarabine and High-Dose Methotrexate in Treating Patients With Central Nervous System Metastases From Breast Cancer
- Depocyt® With Sorafenib in Neoplastic Meningitis
- A Pilot Study of Bevacizumab for Neoplastic Meningitis
- Study to Demonstrate the Safety of WBR Administered at the Same Time as Intrathecal Liposomal Cytarabine (DepoCyte®) Versus Intrathecal Liposomal Cytarabine (DepoCyte®) Administered After WBR for the Treatment of Solid Tumour Neoplastic Meningitis
- A Study to Assess the Efficacy of Erlotinib for Leptomeningeal Carcinomatosis in EGFR Mutation Positive Non-small Cell Lung Cancer
- Phase 1 Intrathecal Topotecan for Neoplastic Meningitis
- A Safety Study of RTA 744 in Recurrent, Progressive or Refractory Neoplastic Meningitis
- DepoCyt for Active Lymphomatous or Leukemic Meningitis
- DepoCyt Plus Temozolomide in Patients With Neoplastic Meningitis
- RTA 744 Injection in Patients With Leptomeningeal Disease
- Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases
- High Dose Gefitinib for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations
- A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis
- Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors
- Intrathecal Gemcitabine to Treat Neoplastic Meningitis, IT Gemcitabine
- DepoCyt Therapy in Patients With Neoplastic Meningitis From Lymphoma or a Solid Tumor
- Temozolomide in Treating Patients With Leptomeningeal Metastases From a Solid Tumor or Lymphoma
- Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment
- Melphalan in Patients With Neoplastic Meningitis